Hereditary Angioedema Therapeutics Market Report 2025

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from $6.68 billion in 2024 to $7.84 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, and regulatory approvals.

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $16.11 billion in 2029 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, and collaboration in research and treatment. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, and pediatric HAE therapeutics.

The anticipated rise in the prevalence of hereditary angioedema is expected to drive the growth of the hereditary angioedema market in the future. Hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent severe swelling of the skin and mucous membranes, affects approximately 1 in every 50,000 individuals globally, with prevalence estimates ranging from 1,10,000 to 1,150,000. These episodes result in 15,000 to 30,000 emergency room visits annually in the US alone. The increasing incidence of hereditary angioedema is a significant factor propelling the growth of the hereditary angioedema market.

The rising healthcare expenditure is projected to enhance the growth of the hereditary angioedema therapeutics market in the future. Healthcare expenditure refers to the total resources, including financial investments, allocated for healthcare goods and services within a specific timeframe in a defined geographical area. Increased healthcare spending facilitates greater investment in research and development aimed at understanding the underlying causes of hereditary angioedema and creating innovative therapeutic solutions. For instance, in December 2022, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that U.S. healthcare spending increased by 4.1% to reach $4.5 trillion in 2022, surpassing the 3.2% growth seen in 2021. Therefore, the rise in healthcare expenditure is propelling the growth of the hereditary angioedema therapeutics market.

A notable trend gaining traction in the hereditary angioedema therapeutics market is the emphasis on product innovation. Leading companies in this market are actively involved in the development of groundbreaking products, including ligand-conjugated (LICA) investigational antisense medicine and gene therapy, to reinforce their market position. In a significant development, Intellia Therapeutics, a clinical-stage biotechnology company based in the US, introduced an Investigational New Drug (IND) named NTLA-2002 in March 2023. This innovative therapy, approved by the United States Food and Drug Administration for hereditary angioedema treatment, allows the company's ongoing Phase 1/2 trial to incorporate the US into the global Phase 2 segment. NTLA-2002, a candidate for in vivo genome editing, aims to permanently lower plasma kallikrein protein activity and prevent hereditary angioedema attacks after a single dose of therapy through the inactivation of the target gene, kallikrein B1 (KLKB1).

Key companies in the hereditary angioedema (HAE) therapeutics market are focusing on developing innovative treatments, such as oral plasma kallikrein inhibitors, to improve patient management and provide effective on-demand solutions for alleviating HAE attacks. These oral medications work by inhibiting the enzyme plasma kallikrein, which helps manage and lessen the severity of hereditary angioedema episodes. For example, in September 2024, KalVista Pharmaceuticals, a U.S.-based biopharmaceutical company, received a new drug application approval from the U.S. Food and Drug Administration for Sebetralstat. This treatment aims to provide HAE patients with a more convenient, non-invasive alternative to intravenous or subcutaneous therapies. It addresses the increasing demand for rapid and effective oral treatments that can be administered immediately during an HAE attack, thereby enhancing overall patient outcomes and quality of life.

In February 2023, Takeda Pharmaceutical Company acquired Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC. The acquisition, involving an undisclosed amount, enhances Takeda's late-stage pipeline, contributing to portfolio expansion and broadening its impact across multiple indications. Nimbus Lakshmi is a US-based company specializing in Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary angioedema therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hereditary angioedema (HAE) therapeutics pertain to the treatment of an autosomal dominant condition caused by a deficiency or malfunction of the C1-inhibitor protein. Symptoms of hereditary angioedema include angioedema-related upper airway, cutaneous, and/or gastrointestinal complaints.

The main drug classes of hereditary angioedema therapeutics include C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. C1 Esterase Inhibitor is a protein present in the fluid portion of blood that regulates the complement system's protein C1. These therapeutics are administered through intravenous, subcutaneous, and oral routes and are distributed via hospital pharmacies, retail pharmacies, and others. The application of hereditary angioedema therapeutics includes prophylaxis and on-demand treatment.

The hereditary angioedema therapeutics market research report is one of a series of new reports that provides hereditary angioedema therapeutics market statistics, including hereditary angioedema therapeutics industry global market size, regional shares, competitors with a hereditary angioedema therapeutics market share, detailed hereditary angioedema therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. This hereditary angioedema therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. he hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.